It functions to disrupt cellular metabolism.
US Patent Issued to Biogen Idec MA on June 4 for "Methods for Inhibiting Lymphotoxin-.Beta. Receptor Signaling in TH1 Cell-Associated Disorders" (Massachusetts Inventors)
Jun 05, 2013; ALEXANDRIA, Va., June 5 -- United States Patent no. 8,455,445, issued on June 4, was assigned to Biogen Idec MA Inc. (Cambridge,...